carbostyril has been researched along with Multiple Sclerosis in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (16.07) | 29.6817 |
| 2010's | 40 (71.43) | 24.3611 |
| 2020's | 7 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, C; Chrzanowski, U; Kaye, J; Kipp, M; Nyamoya, S; Schmitz, C; Steinle, J | 1 |
| Behrangi, N; Brendel, M; Jiangshan, Z; Kaye, J; Kipp, M; Nedelcu, J; Reinbach, C; Riedler, P; Rominger, A; Schmitz, C | 1 |
| Abbastabar, H; Bitarafan, S; Harirchian, MH; Mohammadpour, Z; Noureini, SK; Rouhi, F | 1 |
| Choudhary, M; Malek, G | 1 |
| Berghoff, M; Böttiger, G; Dentzien, N; Ergün, S; Karnati, S; Rajendran, R; Rajendran, V; Sharifi, B; Stadelmann, C | 1 |
| Boyko, A; Comi, G; Dadon, Y; Filippi, M; Halevy, N; Knappertz, V; Lublin, FD; Montalban, X; Rocca, MA; Rubinchick, S; Sasson, N; Steinerman, JR; Vermersch, P; Volkinshtein, R; Vollmer, TL; Ziemssen, T | 1 |
| Farinas, MF; Jeffers, M; Kakuk-Atkins, L; Kraus, EE; Lovett-Racke, AE; Yang, Y | 1 |
| Faissner, S; Gold, R | 1 |
| Elgart, A; Eyal, E; Mimrod, D; Morganroth, J; Rabinovich, L; Samara, E; Spiegelstein, O; Sprenger, C | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Bifulco, M; D'Alessandro, A; Gazzerro, P; Laezza, C; Macchia, M; Malfitano, AM; Manera, C; Matarese, G; Procaccini, C; Saccomanni, G; Tuccinardi, T | 1 |
| Barilan, O; Gilmore, W; Hayardeny, L; Kelland, EE; Lund, BT; Weiner, LP | 1 |
| Boyko, AN; Comi, G; De Stefano, N; Filippi, M; Jeffery, D; Kappos, L; Montalban, X; Pagani, E; Rocca, MA | 1 |
| Tur, C | 1 |
| Gold, R; Thöne, J | 1 |
| Gold, R | 2 |
| Arnold, DL; Cohen, JA; Gilgun-Sherki, Y; Havrdova, E; Sasson, N; Selmaj, K; Sorensen, PS; Vollmer, TL; Zipp, F | 1 |
| Schulze-Topphoff, U; Varrin-Doyer, M; Zamvil, SS | 1 |
| di Nuzzo, L; Nasca, C; Nicoletti, F; Orlando, R | 1 |
| Barnett, MH; Boggild, M; Brew, BJ; Broadley, SA; Butzkueven, H; Carroll, WM; Heard, R; Hodgkinson, S; Kermode, AG; Kilpatrick, TJ; King, J; Lechner-Scott, J; Macdonell, RA; Marriott, M; Mason, DF; McCombe, PA; Parratt, J; Pollard, JD; Reddel, SW; Shaw, CP; Slee, M; Spies, J; Taylor, BV; Willoughby, E | 1 |
| Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE | 1 |
| Abdollahi, M; Nikfar, S; Safavi, M | 1 |
| Caserta, C; D'Amico, E; Leone, C; Patti, F | 1 |
| Kretzschmar, B; Pellkofer, H; Weber, MS | 1 |
| Linker, RA; Thöne, J | 1 |
| Bifulco, M; Laezza, C; Malfitano, AM; Manera, C; Pisanti, S | 1 |
| Annus, A; Majlath, Z; Vecsei, L | 1 |
| Annunziata, P; Cioni, C; Corelli, F; Mugnaini, C | 1 |
| Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G | 1 |
| Smith, EJ | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H | 1 |
| Gasperini, C; Ruggieri, S | 1 |
| Fontoura, P; Garren, H | 1 |
| Fox, EJ | 1 |
| Christopher, EJ; Gagliardi, JP; Kahn, DA; Muzyk, AJ | 1 |
| Fernández, O | 1 |
| Jadidi-Niaragh, F; Mirshafiey, A | 1 |
| Brück, W; Wegner, C | 1 |
| Csépány, T | 1 |
| Arnett, HA; Cee, VJ; Croghan, MD; Fiorino, M; Fotsch, C; Frohn, MJ; Harrington, PE; Horner, M; Lanman, BA; Lee, MR; McElvain, M; Morrison, HG; Pennington, LD; Pickrell, AJ; Reed, AB; Sham, KK; Tasker, AS; Wong, M; Xu, H; Xu, Y; Zhang, X | 1 |
| Comi, G; Conrad, R; Ellrichmann, G; Gold, R; Hayardeny, L; Lee, DH; Linker, RA; Peruga, I; Seubert, S; Thöne, J; Wiese, S | 1 |
| Graham-Rowe, D | 1 |
| Aharoni, R; Arnon, R; Eilam, R; Hayardeny, L; Saada, R; Sela, M | 1 |
| Mack, M; Mishra, MK; Silva, C; Wang, J; Yong, VW | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Lassmann, H | 1 |
| Hayardeny, L; Melamed, D; Miller, A; Nussbaum, S; Snir, A; Staun-Ram, E; Toubi, E | 1 |
| Bandichhor, R; Iqbal, J; Mulakayala, N; Oruganti, S; Rao, P | 1 |
| Methner, A; Zipp, F | 1 |
| Aström, M; Brodin, T; Brunmark, C; Hedlund, G; Ohlsson, L; Runström, A; Sparre, B | 1 |
| Aderhold, V; Haasen, C; Lambert, M; Reimer, J | 1 |
| Fristedt, T; Jansson, K; Jönsson, S; Olsson, A; Svensson, B | 1 |
| Edman, K; Gunnarsson, PO; Hansson, G; Olin, M; Sennbro, CJ; Svensson, LD | 1 |
| Burton, JM; O'Connor, P | 1 |
26 review(s) available for carbostyril and Multiple Sclerosis
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.
Topics: Adult; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2020 |
The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Biotransformation; Central Nervous System; Cytochrome P-450 Enzyme System; Disease Models, Animal; Eye Diseases; Eye Proteins; Gene Expression Regulation; Helix-Loop-Helix Motifs; Humans; Ligands; Mammals; Molecular Targeted Therapy; Multiple Sclerosis; Nerve Degeneration; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Polychlorinated Dibenzodioxins; Quinolones; Rats; Receptors, Aryl Hydrocarbon; Signal Transduction; Transcription, Genetic; Xenobiotics | 2020 |
Oral Therapies for Multiple Sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2019 |
Review of laquinimod and its therapeutic potential in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP3A; Drug Evaluation, Preclinical; Humans; Multiple Sclerosis; Neuroprotective Agents; Quinolones | 2013 |
Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Multiple Sclerosis; Quinolones | 2014 |
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immune System; Multiple Sclerosis; NF-E2-Related Factor 2; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neur
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antioxidants; Australia; Clinical Trials, Phase III as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Disease Management; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; New Zealand; Nitriles; Quinolones; Randomized Controlled Trials as Topic; Therapies, Investigational; Toluidines; Transplantation, Autologous; Treatment Outcome | 2014 |
[Oral treatments in multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
A systematic review of drugs in late-stage development for the treatment of multiple sclerosis: a focus on oral synthetic drugs.
Topics: Benzamides; Humans; Immunologic Factors; Multiple Sclerosis; Piperidines; Pyridines; Quinolones; Small Molecule Libraries; Thiazoles | 2015 |
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.
Topics: Administration, Oral; Clinical Trials as Topic; Cytokines; Drugs, Investigational; Humans; Immunosuppressive Agents; Multiple Sclerosis; Quinolones | 2015 |
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Topics: Animals; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Toluidines | 2016 |
Laquinimod in the treatment of multiple sclerosis: a review of the data so far.
Topics: Humans; Multiple Sclerosis; Neuroprotective Agents; Quinolones | 2016 |
Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod.
Topics: Animals; Brain; Disease Progression; Drug Development; Humans; Kynurenine; Molecular Targeted Therapy; Multiple Sclerosis; Neuroprotective Agents; Quinolones; Young Adult | 2018 |
Emerging oral drugs for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2008 |
New oral drugs for multiple sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Emerging oral agents for multiple sclerosis.
Topics: 4-Aminopyridine; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Quinolones; Sphingosine | 2010 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Oral laquinimod treatment in multiple sclerosis.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Sclerosis; Quinolones | 2011 |
Therapeutic approach to multiple sclerosis by novel oral drug.
Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Topics: Cladribine; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Molecular Structure; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Small Molecule Libraries; Sphingosine; Toluidines | 2013 |
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
Topics: Clinical Trials as Topic; Dimethyl Fumarate; Fumarates; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Potassium Channels, Inwardly Rectifying; Quinolones; Receptors, Tumor Necrosis Factor, Type I; T-Lymphocytes | 2013 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
7 trial(s) available for carbostyril and Multiple Sclerosis
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Topics: Double-Blind Method; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Recurrence | 2022 |
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
Topics: Adolescent; Adult; Double-Blind Method; Electrocardiography; Female; Heart; Heart Rate; Humans; Huntington Disease; Immunologic Factors; Long QT Syndrome; Male; Middle Aged; Multiple Sclerosis; Quinolones; Young Adult | 2019 |
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
Topics: Adult; Cohort Studies; Female; Humans; Immunologic Surveillance; Leukocytes, Mononuclear; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Quinolones; Treatment Outcome | 2013 |
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Creatinine; Disability Evaluation; Endpoint Determination; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Multiple Sclerosis; Quinolones; Thalamus; Treatment Outcome; Young Adult | 2014 |
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Topics: Adolescent; Adult; Endpoint Determination; Female; Humans; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Quinolones; Recurrence; Risk Assessment; Young Adult | 2014 |
Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling.
Topics: Chromatography, High Pressure Liquid; Humans; Immunologic Factors; Multiple Sclerosis; Quinolones; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2006 |
24 other study(ies) available for carbostyril and Multiple Sclerosis
| Article | Year |
|---|---|
Laquinimod Supports Remyelination in Non-Supportive Environments.
Topics: Animals; Brain; Cell Differentiation; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Myelin Sheath; Oligodendrocyte Transcription Factor 2; Oligodendroglia; Quinolones; Remyelination | 2019 |
Laquinimod ameliorates secondary brain inflammation.
Topics: Animals; Brain; Cuprizone; Disease Models, Animal; Encephalitis; Female; Gliosis; Mice, Inbred C57BL; Multiple Sclerosis; Quinolones | 2020 |
Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes.
Topics: Animals; Benzamides; Benzimidazoles; Cell Line; Multiple Sclerosis; Oligodendroglia; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Quinolones; Rats; Receptor, Fibroblast Growth Factor, Type 1; Remyelination | 2021 |
Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
Topics: Adult; Animals; Autoimmunity; CD4-Positive T-Lymphocytes; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Box Protein O1; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Multiple Sclerosis; Quinolones | 2021 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.
Topics: Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Lectins, C-Type; Lymphocyte Activation; Multiple Sclerosis; Myelin Basic Protein; Naphthyridines; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyridones; Quinolones; Receptor, Cannabinoid, CB2; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2013 |
Oral laquinimod for multiple sclerosis: beyond the anti-inflammatory effect.
Topics: Brain; Female; Humans; Male; Multiple Sclerosis; Quinolones | 2014 |
[Immunomodulation with oral dosage forms and their mechanisms of action].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Toluidines | 2013 |
Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis.
Topics: Anti-Inflammatory Agents; Apoptosis; Case-Control Studies; CD4 Antigens; Cell Cycle; Cell Proliferation; Cell Survival; Cytokines; Gene Expression; Humans; Lymphocytes; Multiple Sclerosis; Phosphorylation; Quinolones; Receptor, Cannabinoid, CB2; T-Lymphocytes | 2016 |
Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
Topics: Adamantane; Adult; Cannabinoid Receptor Agonists; Cells, Cultured; Cytokines; Female; Humans; Immunologic Factors; Leukocytes, Mononuclear; Male; Multiple Sclerosis; Quinolones; Receptor, Cannabinoid, CB2; T-Lymphocytes | 2017 |
Multiple sclerosis presenting with erotomanic delusions in the context of "Don't ask, don't tell".
Topics: Adjuvants, Immunologic; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Erotica; Female; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Military Personnel; Military Psychiatry; Multiple Sclerosis; Organizational Policy; Piperazines; Quinolones; Recognition, Psychology; Schizophrenia, Paranoid; Sex Offenses; Sexual Harassment; Stress, Psychological; Syndrome | 2009 |
The future of multiple sclerosis therapy.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
Use of aripiprazole in a patient with multiple sclerosis presenting with paranoid psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Multiple Sclerosis; Paranoid Disorders; Piperazines; Quinolones; Treatment Outcome | 2010 |
Insight into the mechanism of laquinimod action.
Topics: Analysis of Variance; Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Movement; Central Nervous System; Clinical Trials, Phase II as Topic; Cytokines; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Humans; Immunologic Factors; Interferon-beta; Leukocytes; Mice; Microscopy, Electron, Transmission; Multiple Sclerosis; Quinolones; Rats | 2011 |
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2012 |
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, Inbred C57BL; Monocytes; Multiple Sclerosis; Neuroprotective Agents; Quinolones | 2012 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Topics: Animals; Axons; Brain-Derived Neurotrophic Factor; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Immunologic Factors; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroprotective Agents; Quinolones; T-Lymphocytes, Regulatory | 2012 |
Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.
Topics: Animals; Cell Count; Cell Movement; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Activation; Female; Humans; Inflammation; Kinetics; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocytes; Multiple Sclerosis; NF-kappa B; Quinolones; Spinal Cord | 2012 |
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Topics: Animals; Astrocytes; Blood-Brain Barrier; Ceramides; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; NF-kappa B; Oligodendroglia; Propylene Glycols; Quinolones; Sphingosine | 2012 |
Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.
Topics: Adult; B-Lymphocytes; B7-2 Antigen; Cells, Cultured; Coculture Techniques; Female; Humans; Immunologic Factors; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Interleukin-4; Male; Middle Aged; Multiple Sclerosis; Quinolones; T-Lymphocytes; Transforming Growth Factor beta; Young Adult | 2012 |
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; B-Lymphocytes; Cells, Cultured; Central Nervous System; Chemotaxis, Leukocyte; Dexamethasone; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Hydroxyquinolines; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroimmunomodulation; Quinolones; T-Lymphocytes | 2002 |
Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diet; Epilepsy, Generalized; Female; Hallucinations; Humans; Hypnotics and Sedatives; Hypothyroidism; Lorazepam; Magnetic Resonance Imaging; Multiple Sclerosis; Paranoid Disorders; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation.
Topics: Ethylenes; Hydrogen Bonding; Ketones; Kinetics; Multiple Sclerosis; Nitrogen; Protons; Quinolones; Solvents | 2006 |